Tocqueville Asset Management L.P. Makes New $1.50 Million Investment in The Cooper Companies, Inc. $COO

Tocqueville Asset Management L.P. purchased a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the second quarter, HoldingsChannel.com reports. The fund purchased 20,952 shares of the medical device company’s stock, valued at approximately $1,502,000.

Several other institutional investors have also modified their holdings of the business. Avalon Trust Co bought a new stake in Cooper Companies during the 2nd quarter worth approximately $25,000. Root Financial Partners LLC lifted its stake in Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. lifted its stake in Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC boosted its holdings in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the period. Finally, J.Safra Asset Management Corp acquired a new position in shares of Cooper Companies in the second quarter valued at approximately $32,000. Institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: The company’s latest reported quarter showed solid operating performance: adjusted earnings of $1.21 per share exceeded consensus by $0.11, revenue reached $1.08 billion versus expectations of $1.05 billion, and sales increased 7.9% year over year. COO also maintained fiscal 2026 EPS guidance of $4.58–$4.66.
• Neutral Sentiment: Recent headlines mentioning “Cooper,” “COO,” or cooperation—including Bass Oil’s Cooper Basin update, Wendy’s discussion of a chief operating officer role, and Trainline’s regulatory cooperation—do not concern The Cooper Companies and are not relevant catalysts for COO.
• Negative Sentiment: With no fresh corporate catalyst in the provided articles, the modest weakness may reflect normal trading, profit-taking, or valuation concerns. The stock trades at a relatively high price-to-earnings multiple of about 64.5, leaving shares sensitive to changes in investor expectations even after the recent earnings beat.

Cooper Companies Price Performance

Shares of COO opened at $76.16 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a twelve month low of $58.89 and a twelve month high of $89.83. The stock has a market capitalization of $14.85 billion, a P/E ratio of 64.54, a P/E/G ratio of 2.01 and a beta of 0.83. The company has a 50 day moving average of $71.76 and a 200-day moving average of $71.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm posted $0.96 earnings per share. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

COO has been the topic of a number of research analyst reports. Stifel Nicolaus dropped their price objective on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. JPMorgan Chase & Co. reduced their target price on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research note on Friday, June 5th. Wells Fargo & Company reiterated a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a report on Friday, June 5th. Citigroup reissued a “neutral” rating and issued a $80.00 price target (up from $76.00) on shares of Cooper Companies in a research note on Thursday, August 13th. Finally, Needham & Company LLC cut their price target on Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $81.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.